“During the first quarter of 2024, we focused on execution across our pipeline including delivering on our near-term milestones for TYRA-300 in both achondroplasia and oncology,” said Todd Harris, CEO of TYRA. “In oncology, the TYRA-300 clinical profile continues to mature in SURF301, and our clinical team is focused on Part B dose expansion to evaluate multiple dosing regimens of TYRA-300. We believe this work will support future Phase 2 studies in NMIBC and metastatic urothelial carcinoma, where we see tremendous opportunity for an oral FGFR3-selective inhibitor. In achondroplasia, we remain on track to submit our IND in the second half of 2024 to support our planned Phase 2 study.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
- Tyra Bioscience Expands Board with Two New Appointments
- Tyra Bioscience Gains Pediatric Disease Designation for Achondroplasia Drug Amid FDA Voucher Uncertainty
- Tyra Biosciences price target raised to $23 from $19 at H.C. Wainwright
- Tyra Biosciences files to sell 15.37M shares of common stock for holders